Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 2. Oncologist. 2004;9(4):422-41. doi: 10.1634/theoncologist.9-4-422. Biology and therapeutic advances for pediatric osteosarcoma. Marina N(1), Gebhardt M, Teot L, Gorlick R. Author information: (1)Department of Pediatrics, Division of Hematology-Oncology, Stanford University Medical Center, Stanford, California 94305-5208, USA. Neyssa.marina@stanford.edu Osteosarcoma is the most common malignant bone tumor in children and adolescents. Survival for these patients was poor with the use of surgery and/or radiotherapy. The introduction of multi-agent chemotherapy dramatically improved the outcome for these patients and the majority of modern series report 3-year disease-free survival of 60%-70%. This paper describes current strategies for treating patients with osteosarcoma as well as review of the clinical features, radiologic and diagnostic work-up, and pathology. The authors review the state of the art management for patients with osteosarcoma in North America and Europe including the use of limb-salvage procedures and reconstruction as well as discuss the etiologic and biologic factors associated with tumor development. Therapy-related sequelae and future directions in the biology and therapy for these patients are also discussed. Copyright AlphaMed Press DOI: 10.1634/theoncologist.9-4-422